Senti Biosciences, Inc. SNTI stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.The company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia.SENTI-202 is designed to selectiv ...

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. “Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results fro ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CARNK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright's 26th Annual Global Investment Conference Format: Prese ...

Financial Performance - Senti Bio reported a net loss of $11.2 million for Q2 2024, compared to $18.7 million in the same period in 2023[4][10] - Cash and cash equivalents stood at $15.9 million as of June 30, 2024, down from $35.9 million at the end of 2023[4][9] - Total assets decreased to $86.9 million as of June 30, 2024, from $119.5 million at the end of 2023[9] Research and Development (R&D) - R&D expenses increased to $9.2 million in Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs for wholly-owned programs[4][10] - Senti Bio received an $8 million grant from CIRM to support the clinical development of SENTI-202 for relapsed/refractory hematologic malignancies[2] - Patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for AML, with initial efficacy data expected by year-end 2024[3] - Senti Bio plans to initiate a pilot trial of SENTI-301A for hepatocellular carcinoma in China through a partnership with Celest, with first patient dosing expected in Q4 2024[3] General and Administrative (G&A) Expenses - G&A expenses decreased to $4.2 million in Q2 2024, down from $9.2 million in Q2 2023, mainly due to a reduction in headcount[4][10] Corporate Actions - The company effected a 1-for-10 reverse stock split in July 2024 to comply with Nasdaq's minimum bid price requirement[3] Receivables and Transactions - Senti Bio anticipates $18.9 million in receivables from the GeneFab transaction upon satisfaction of certain conditions[4]

Core Insights - Senti Biosciences, Inc. is advancing its clinical trials for SENTI-202, targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][4] - The company has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SENTI-202 [3] - Senti Bio is also preparing to initiate a pilot trial for SENTI-301A in hepatocellular carcinoma (HCC) in China through a partnership with Celest Therapeutics [2][5] Corporate and Pipeline Highlights - The Phase 1 clinical trial for SENTI-202 has commenced, focusing on patients with relapsed/refractory AML in the U.S. and Australia, with initial efficacy data expected by the end of 2024 [4] - The company is developing SENTI-301A for solid tumors in China, with the first patient expected to be dosed in Q4 2024 [5] - A reverse stock split of 1-for-10 was executed in July 2024 to comply with Nasdaq's minimum bid price requirement [6] Financial Results - As of June 30, 2024, Senti Bio reported cash and cash equivalents of $15.9 million, with additional receivables of $18.9 million anticipated from the GeneFab transaction [7] - Research and development expenses increased to $9.2 million for Q2 2024, up from $6.9 million in Q2 2023, primarily due to manufacturing costs [7] - General and administrative expenses decreased to $4.2 million in Q2 2024 from $9.2 million in Q2 2023, attributed to a reduction in headcount [7] Upcoming Events - Senti Bio plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and Chardan's 8th Annual Genetic Medicines Conference from September 30 to October 1, 2024 [8]

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant wil ...

Core Insights - Senti Biosciences, Inc. has received an $8 million grant from the California Institute for Regenerative Medicines to support the clinical development of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia [1][2] Company Overview - Senti Bio is a biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to create therapies with enhanced precision and control [6] - The company is advancing its pipeline with off-the-shelf CAR-NK cells designed to target challenging liquid and solid tumor indications [6] Product Development - SENTI-202 is a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells [3] - The therapy includes three main components: an OR GATE for activating CAR targeting, a NOT GATE for protecting healthy cells, and calibrated-release IL-15 technology to enhance cell persistence and activity [3] - A Phase 1 clinical trial for SENTI-202 is currently enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies, with initial efficacy data expected by the end of 2024 [2][3] Market Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [5] - Current treatment options for relapsed or refractory AML are limited, with median overall survival typically less than seven months [5]

Forward-Looking Statements This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including statements with respect to Senti Bio's ability to regain compliance with Nasdaq's continued listing standards and remain listed on Nasdaq or any other major stock exchange and other statements that are forwar ...

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio") , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a onefor-ten (1-for-10) reverse stock split of Senti Bio's common stock, par value $0.0001 per share (the "Common Stock"). The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and S ...

Core Insights - Senti Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SENTI-202, a potential first-in-class CAR-NK cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [6][2][3] - The Phase 1 clinical trial of SENTI-202 is currently enrolling patients, with initial efficacy data expected by the end of 2024 and durability data anticipated in 2025 [6][11] Company Overview - Senti Bio is a biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in targeting cancer cells while sparing healthy cells [8][2] - The company utilizes off-the-shelf CAR-NK cells outfitted with Gene Circuits to target challenging liquid and solid tumor indications, demonstrating potential in various modalities and diseases beyond oncology [8][12] Industry Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases expected in the United States in 2024 and a five-year survival rate of approximately 30% [3][2] - Current treatment options for AML include chemotherapy, targeted therapies, and stem cell transplants, but there are limited options for patients with relapsed or refractory AML, with median overall survival typically less than seven months [3][2]